Mizuho Maintains Buy on Adaptimmune Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Adaptimmune Therapeutics (NASDAQ:ADAP) but lowers the price target from $9 to $3.

May 17, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Adaptimmune Therapeutics but significantly lowers the price target from $9 to $3.
The significant reduction in the price target from $9 to $3 suggests a more cautious outlook on the stock's potential, which could lead to a negative short-term impact on the stock price despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100